# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Edward White maintains TG Therapeutics (NASDAQ:TGTX) with a Buy and raises the price target ...
Ladenburg Thalmann analyst Matthew Kaplan maintains TG Therapeutics (NASDAQ:TGTX) with a Buy and raises the price target fro...
TGTX: 31% | TG Therapeutics shares are trading higher following a Q1 revenue beat and increased 2024 Briumvi US net product rev...
TGTX: 31% | TG Therapeutics shares are trading higher following a Q1 revenue beat and increased 2024 Briumvi US net product rev...